Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I dose-escalation study of CST-101 in patients with Advanced Renal Cell Carcinoma and Melanoma susceptible to immunotherapies.

Next Previous
Trial Profile

A phase I dose-escalation study of CST-101 in patients with Advanced Renal Cell Carcinoma and Melanoma susceptible to immunotherapies.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CST 101 (Primary)
  • Indications Malignant melanoma; Renal cell carcinoma
  • Focus Adverse reactions

Most Recent Events

  • 17 Mar 2016 New trial record
  • 07 Feb 2016 Clinical data from the first 12 patients of the U.S. trial at Rush University Medical Center in Chicago has been announced recently, as per the University of Pittsburgh Medical Center (UPMC) media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top